Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

Stroke Clinical Trial

— CANNASTROKE  

Official title:

Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03379857
• Other study ID #: 6640
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 11, 2018
• Est. completion date: January 11, 2025

Study information

• Verified date: February 2024
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects.

There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 300
• Est. completion date: January 11, 2025
• Est. primary completion date: January 11, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Subject between 18 and 45 years old

• Stroke confirmed by medical imaging

• Written informed consent (subject, nearby or emergency procedure)

• Subject affiliate to a local healthcare insurance office

• For female of childbearing potential, an adequate contraceptive measur

Exclusion Criteria:

• Subject with psychiatric disorder, unable to understand the study or cooperate

• Subject under guardianship or forfeiture of liberty

• Pregnant or breastfeeding woman

• Subject in period of exclusion due to another study or still in follow-up of an interventional study

Related Conditions & MeSH terms

• Cannabis Use
• Ischemic Stroke
• Marijuana Abuse
• Stroke

Intervention

Other:
• Drug urinal test
Non Applicable

Locations

Country	Name	City	State
France	Chu Jean Minjoz	Besancon
France	Unite Neuro-Vasculaire	Colmar
France	Chu Bocage	Dijon
France	C.H. G. Muller	Mulhouse
France	Hopital Central	Nancy
France	Les Hôpitaux Universitaires de Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation Cannabis use		12 months
Primary	Reversible vasoconstriction on medical imaging of intracranial arteries at different moment	medical imaging of intracranial arteries will show new stenoses (topography, number, evolution), and new ischemic or cerebral haemorrhagic lesions	12 months.